Abstract: The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Abstract: The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating ng disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Abstract: The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Abstract: A method of identifying proteins present in human serum which are differentially expressed between normal individuals and patients known to have non-small cell lung cancers and asthma, as diagnosed by a physician. Human serum specimens from each population are digested with trypsin or any other suitable endoproteinase and analyzed using a liquid chromatography electrospray ionization mass spectrometer. Mass spectral data from each population is compared to determine proteins with expression intensities which are significantly differentially expressed between the normal, asthma, and lung cancer populations. Eleven proteins are found to have expression intensities which are significantly differentially expressed between the populations. Finally, the identities of the eleven proteins are obtained by comparing the mass spectral data with known databases having libraries of mass spectral data of known proteins.

Abstract: A method of identifying proteins present in human serum which are differentially expressed between normal individuals and patients known to have non-small cell lung cancers and asthma, as diagnosed by a physician. Human serum specimens from each population are digested with trypsin or any other suitable endoproteinase and analyzed using a liquid chromatography electrospray ionization mass spectrometer. Mass spectral data from each population is compared to determine proteins with expression intensities which are significantly differentially expressed between the normal, asthma, and lung cancer populations. Eleven proteins are found to have expression intensities which are significantly differentially expressed between the populations. Finally, the identities of the eleven proteins are obtained by comparing the mass spectral data with known databases having libraries of mass spectral data of known proteins.

Abstract: The invention provides biomarkers and combinations of biomarkers that are useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Abstract: The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subjects response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Abstract: A method of identifying altered biomarker expression levels in a human serum specimen to diagnose asthma or non-small celled lung cancers in humans. The existence of asthma or non-small celled lung cancers in a patient can be determined by subjecting a blood sample from the patient to a simple blood test to determine the expression levels of certain specific biomarkers. The expression levels of the specific biomarkers are compared to ranges of expression levels for the same biomarkers which are indicative of individuals known to have asthma, non-small cell lung cancers, or neither. Comparing the expression levels will determine the existence or non-existence of asthma or non-small cell lung cancer.

Abstract: The invention provides biomarkers and combinations of biomarkers that are useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Abstract: A method of identifying altered biomarker expression levels in a human serum specimen to diagnose asthma or non-small celled lung cancers in humans. The existence of asthma or non-small celled lung cancers in a patient can be determined by subjecting a blood sample from the patient to a simple blood test to determine the expression levels of certain specific biomarkers. The expression levels of the specific biomarkers are compared to ranges of expression levels for the same biomarkers which are indicative of individuals known to have asthma, non-small cell lung cancers, or neither. Comparing the expression levels will determine the existence or non-existence of asthma or non-small cell lung cancer.

Abstract: A method of identifying proteins present in human serum which are differentially expressed between normal individuals and patients known to have non-small cell lung cancers and asthma, as diagnosed by a physician. Human serum specimens from each population are digested with trypsin or any other suitable endoproteinase and analyzed using a liquid chromatography electrospray ionization mass spectrometer. Mass spectral data from each population is compared to determine proteins with expression intensities which are significantly differentially expressed between the normal, asthma, and lung cancer populations. Eleven proteins are found to have expression intensities which are significantly differentially expressed between the populations. Finally, the identities of the eleven proteins are obtained by comparing the mass spectral data with known databases having libraries of mass spectral data of known proteins.